SCHEMBL2466795

SCHEMBL2466795

Cc1cc(C)cc(-c2cnc(N)nc2Nc2n[nH]c3ccc(F)cc23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 3/20 0.45
GSK3B P49841 3/20 0.43
GSK3A P49840 2/20 0.43
EGFR P00533 2/20 0.42
RIPK2 O43353 4/20 0.40
GAK O14976 1/20 0.38
LCK P06239 1/20 0.38
TGFBR1 P36897 1/20 0.38
KCNH2 Q12809 1/20 0.38
MAPK14 Q16539 1/20 0.38
RIPK3 Q9Y572 1/20 0.38
MAP3K14 Q99558 1/20 0.36
GRM4 Q14833 1/20 0.36
RPS6KA3 P51812 1/20 0.35
PDGFRB P09619 1/20 0.35
FGFR1 P11362 1/20 0.35
PDGFRA P16234 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2468419 0.83 ADORA1 (0.46) EGFRFGFR1PIK3CA
SCHEMBL14634163 0.81 RIPK2 (0.48) FADS1GSK3BGSK3AEGFRRIPK2
SCHEMBL14633552 0.80 GSK3A (0.42) FADS1GSK3BGSK3AEGFRRIPK2
SCHEMBL14633702 0.79 RIPK2 (0.46) FADS1GSK3BGSK3AEGFRRIPK2
SCHEMBL14634025 0.79 RIPK2 (0.49) FADS1GSK3BGSK3AEGFRRIPK2
SCHEMBL2514189 0.79 RIPK2 (0.45) FADS1GSK3BGSK3AEGFRRIPK2
SCHEMBL14633730 0.78 RIPK2 (0.40) FADS1GSK3BGSK3AEGFRRIPK2
SCHEMBL2462891 0.78 RIPK2 (0.40) FADS1GSK3BGSK3AEGFRRIPK2
SCHEMBL14633988 0.77 FADS1 (0.39) FADS1GSK3BGSK3AEGFRRIPK2
SCHEMBL14633796 0.76 FADS1 (0.43) FADS1GSK3BGSK3AEGFRRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
EP-2552211-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-02-06 EP disclosed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed
WO-2011120025-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 FADS1 3869/4885GSK3B 896/4885GSK3A 644/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 FADS1 3953/4885GSK3B 710/4885GSK3A 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.